AstraZeneca sells Astra Tech to DENTSPLY for approximately USD 1.8 billion
AstraZeneca has agreed to sell Astra Tech AB to DENTSPLY International Inc for approximately USD 1.8 billion in cash, subject to regulatory clearance.
Astra Tech AB is a global leader in dental and healthcare (urological and surgical) products, services and support headquartered in Mölndal, Sweden, with production facilities in Sweden and North America. The company is active globally, with subsidiaries in 21 countries and select local distribution partners. Astra Tech has 2,200 employees worldwide and recorded $535 million in revenue for 2010. DENTSPLY manufactures and distributes professional, high quality dental product solutions in 120 countries. AstraZeneca is a global, integrated biopharmaceutical company with 61,000 employees worldwide.
AstraZeneca was advised by Mannheimer Swartling in the transaction. The firm's team, led by Clas Nyberg and Adam Green, includes partners Jan Holmberg and Oliver Cleblad (Corporate), Henric Diefke (Employees, Pensions and Unions), Stefan Perván Lindeborg (Competition), Mårten Tagaeus (Environmental), Jesper Prytz (Real Estate), Niklas Sjöblom (IP/IT) and Martin Nilsson (Tax). Associates on the matter include, amongst others, Hendrik Kangasmuukko, Philipp Grosskopf, Mikael Moreira, Nelli Schiebeler, Lucas Jonsson, Teresia Mårdh, Johan Holm, Ola Ranstam, Charlotta Kronblad, Henrik Johansson and Karin Bergelin (Corporate), Bita Pourmotamed (Employees, Pensions and Unions), Martin Sundblad and Kristina Björkevik Kovaniemi (Regulatory), Urszula Sieradzka (Competition), Felicia Terénius (Environmental), Rickard Colliander, Jessika Olsén, Sara Nordlund and Pernilla Book (IP/IT), Charlotte Andréasson and Amelie Kvarnström (Real Estate).